Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)-Reference-Cited by-同舟云学术

Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)

Published:2004-01 Issue:5 Volume:22 Page:655-662
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Fountzilas George,Christodoulou Christos,Tsavdaridis Dimitrios,Kalogera-Fountzila Anna,Aravantinos Gerassimos,Razis Evangelia,Kalofonos Haralambos P.,Papakostas Pavlos,Karina Maria,Gogas Helen,Skarlos Dimosthenis

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1081/CNV-200032980

Reference24 articles.

1. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

2. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

3. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

4. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report;Clinical Medicine Insights: Case Reports;2023-01

2. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study;Cancer Biology & Therapy;2018-11-07

3. HER2-Targeted Therapy;Management of Breast Diseases;2016

4. HER2-positive metastatic breast cancer: first-line treatment;Handbook of HER2-Targeted Agents in Breast Cancer;2016

5. HER2-positive metastatic breast cancer: A changing scenario;Critical Reviews in Oncology/Hematology;2015-07